Lilly's Obesity Pill Foundayo Reduces Cardiovascular Risks in Trial

In a late-stage trial involving over 2,700 adults, patients taking Lilly's obesity pill Foundayo showed a 16% lower risk of heart attack, stroke, or cardiovascular death.

16 Apr, 11:53 — 16 Apr, 11:53

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual43d ago

Lilly's obesity pill helps reduce cardiovascular risks in late-stage trial

In the study of more than 2,700 adults, patients taking Foundayo had a 16% lower risk of heart attack, stroke or cardiovascular death.

Read full article →

PERSPECTA

PERSPECTA

Lilly's Obesity Pill Foundayo Reduces Cardiovascular Risks in Trial

Sources

Lilly's obesity pill helps reduce cardiovascular risks in late-stage trial

Related Stories

Amazon's First Customer Receipt Goes Viral, Bezos and Musk React

Yum! Brands Reportedly in Talks to Sell Pizza Hut to LongRange

Mumbai's Dabbawalas Face Decline Amid Remote Work and Rising Costs

Minho Region Embraces a Forward-Looking Vision for the Future

PERSPECTA